Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
2.190
+0.120 (+5.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Immix Biopharma Attends FDA CEO Forum in Washington DC
June 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
June 03, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session.
May 29, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
May 27, 2025
Volume analysis on 2025-05-27: stocks with an unusual volume in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
May 23, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
May 23, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
May 23, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Discover the top movers in Friday's pre-market session.
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 23, 2025
Via
Benzinga
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
May 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 22, 2025
Via
Benzinga
Thursday's after hours session: top gainers and losers
May 22, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
May 22, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
May 21, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
April 23, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
February 10, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
January 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
December 19, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
December 16, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
December 10, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
December 09, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
November 25, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
October 02, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
September 19, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
August 28, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
August 12, 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
July 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
June 17, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
May 13, 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.